Navigation Links
AndroScience Corporation Forms Strategic Alliance With Taiwan Based Orient Europharma to Develop Novel Topical Acne Therapeutic
Date:5/20/2010

ces necessary to complete a critical milestone towards demonstrating ASC-J9® as a safe and efficacious acne treatment.  We maintain that ASC has secured a favorable agreement with a partner focused on long-term strategic goals for the ASC-J9® topical acne product."

Acne and the Androgen Receptor (AR) as a Therapeutic Target:

Acne represents the most common skin disease, affecting 85% of teenagers, 42.5% of men and 50.9% of women between the ages of 20 and 30 years.  Androgen (male hormone) associated with increased of acne development, and the role of hormones as a trigger of sebum production, sebaceous growth and differentiation are well known. However, despite the establishment of androgen activation pathways as an attractive therapeutic target, a topical anti-androgen based therapeutic has never been successfully developed. ASC has discovered and developed a series of active compounds referred as androgen receptor (AR) degradation enhancers (ARD enhancers). ARD enhancer exerts its function through reduction of AR and androgen function in sebaceous glands, which leads to the reduction of sebum secretion and the manifestation of acne.

The ASC-J9® Acne Clinical Program:

Developed as a cream formulation for use in both men and women, ASC-J9® represents the first topical agent directed at modulating the effect of androgens through the AR.  In a previous phase IIa clinical trial, ASC-J9® in cream formulation lowered lesion counts in moderate to severe acne, with the highest dose group demonstrating the largest percent reductions from baseline at week 12 in inflammatory lesion count and total lesion count. No side effects have been noted in either phase I or phase IIa clinical trials.  Recently ASC completed a new formulation of ASC-J9®, which significantly enhancing dermal penetra
'/>"/>

SOURCE AndroScience Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
2. Thoratec Announces Early Termination of HSR Waiting Period for the Sale of ITC to Danaher Corporation
3. Oxford Finance Corporation Facilitates Entry for Reata Pharmaceuticals into Asian Markets
4. Somanetics Corporation Announces 24 Clinical Abstracts on INVOS System Presented at Annual Pediatric Academic Societies National Conference
5. Curexo Technology Corporation Raises $13.2 Million
6. Waters Corporation and NIBRT Partner to Bring Greater Control and Predictability to Biopharmaceutical Processing
7. Volcano Corporation Presentation at Bank of America Merrill Lynch Health Care Conference to Be Webcast
8. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
9. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
10. United Therapeutics Corporation To Announce First Quarter 2010 Financial Results Before Market Open on Thursday, April 29, 2010
11. Usability Sciences Corporation Launches WebIQ Pharma - An Intelligent Survey Tool That Allows Pharma Sites to Measure and Improve Website Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ANTONIO , Jan. 15, 2014 Most osteoporosis ... according to a recent online survey* sponsored by Mission ... among the National Osteoporosis Foundation online support community, revealed ... take medication that comes in a form other than ...
(Date:1/15/2014)...  Novation, the leading health care supply chain expertise, analytics ... (VAR) national contracts that expand its portfolio to provide ... costs. These include manufacturer product and service agreements, as ... ongoing IT consulting support. New Novation ...
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... Pharmaceuticals, Inc.  (Nasdaq: PCRX ) today announced ... from 381 U.S. hospitals who underwent common hospital-based surgical ... data demonstrate that opioid-related adverse events (ORAEs) are associated ... and more than a day increase in length of ...
... 2, 2011  WestPark Capital, Inc. announced the completion of ... total of 2,817,988 shares of common stock and warrants ... were sold, generating gross proceeds of $2,592,549 in the ... new applications for IsoRay,s Cesium-131 technology to treat lung, ...
Cached Medicine Technology:New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 2New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 3New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting 4WestPark Capital, Inc. Announces $2.6 Million IsoRay Offering 2
(Date:4/24/2014)... Foundation has awarded LSU Health Sciences Center New ... grant in the amount of $295,635. The funding ... social and educational backgrounds, underrepresented in the sciences, ... project will provide students with training for 10 ... will be led by Principal Investigator Dr. Fern ...
(Date:4/23/2014)... donors was safe and effective in treating patients ... difficile , according to a new pilot study ... available online. Known as fecal microbiota transplantation, the ... colonoscope or a nasogastric tube. The findings suggest ... readily available to patients. , A growing concern, ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... New Rochelle, NY, April 23, 2014Men whose testosterone falls ... dysfunction and to be overweight and have heart disease ... designed to identify testosterone-deficient men for further testing and ... Journal of Men,s Health , a peer-reviewed publication from ... free on the Journal of Men,s Health ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... Work in primates points to possible weapon against human ... News) -- Researchers have successfully tested several Ebola vaccines ... first human vaccine for one of the world,s deadliest ... cannot be overlooked. We are seeing more and more ...
... has established that patients with a high blood pressure in ... of pumping blood against this pressure. Further, the right ventricle ... is the first Mosaic laureate to gain his doctorate. ... into the cause of high blood pressure in the lungs ...
... in French . , Montreal, March 31, 2008 ... a novel gene responsible for a significant fraction of ALS ... as Lou Gehrigs disease, an incurable neuromuscular disorder that affects ... to five years. , Published in the current online edition ...
... the manufacturer,of the SurgiLance safety lancet, has made ... Foundation (JDRF) to support ongoing research,efforts. MediPurpose made ... of its,500 millionth safety lancet to St. Louis-based ... improving the quality of life for those,living with ...
... 31 ReBuilder,Medical Technologies, Inc. (Pink Sheets: RBRM), ... diabetic peripheral neuropathy, Molluscum,Contagiosum, and MRSA; today reported ... when they sold over $25,000 in products., ... have not been affected thus far by the ...
... Highlights Key Issues and Offers Suggestions on ... Improvements for Hospital Administrators, NEW YORK, March ... delivery of a baby is a significant decision. But,there are ... departments,around the country that must function properly in order to ...
Cached Medicine News:Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Researchers identify a gene responsible for Lou Gehrig's disease 2Health News:MediPurpose Supports Diabetes Research Effort 2Health News:ReBuilder Medical Technologies, Inc. Announces Best Sales Day in 5 Years 2Health News:OB Challenges Create Hospital Opportunities in 2008 2Health News:OB Challenges Create Hospital Opportunities in 2008 3Health News:OB Challenges Create Hospital Opportunities in 2008 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: